Moderna has announced that the first participants have been dosed with the vaccine candidate for children aged 6 mo nths through 16 years-old. This study will evaluate the safety, tolerability, reactogenicity and effectiveness of two doses of mrna-1273 given 28 days apart. The company intends to enroll approximately 6,750 pediatric participants in the U.S. and Canada ages 6 months to less than 12 years.
For more information about the trial, including the process for enrolling participants, please visit www.kidcovestudy.com.
Moderna plans to follow participants for a year after the second vaccination to determine effectiveness.
